Activity of tarloxotinib‐E in cells with EGFR exon‐20 insertion mutations and mechanisms of acquired resistance

BACKGROUND: Approximately 10% of non‐small cell lung cancers (NSCLCs) that harbor epidermal growth factor receptor (EGFR) gene mutations have in‐frame insertions in exon 20 of the EGFR gene. These tumors do not usually respond to currently available EGFR‐tyrosine kinase inhibitors (TKIs). Tarloxotin...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Thorac Cancer
Main Authors: Nishino, Masaya, Suda, Kenichi, Koga, Takamasa, Ohara, Shuta, Fujino, Toshio, Soh, Junichi, Tirunagaru, Vijaya, Vellanki, Avanish, Doebele, Robert C., Mitsudomi, Tetsuya
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons Australia, Ltd 2021
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8107039/
https://ncbi.nlm.nih.gov/pubmed/33710795
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13931
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados